Pretreatment dual-time-point ¹⁸F-FDG PET/CT for predicting response and survival in locally advanced pancreatic cancer receiving neoadjuvant therapy

Accurately identifying patients with locally advanced pancreatic cancer (LAPC) who are unlikely to respond to neoadjuvant FOLFIRINOX therapy remains a critical unmet need. Conventional anatomic imaging often fails to capture early changes in tumor biology. In contrast, dual-time-point ¹⁸F-FDG PET/CT provides a functional assessment of tumor glycolytic dynamics through the retention index (RI). However, the utility of pretreatment RI for predicting treatment response and overall survival (OS) in LAPC has not been systematically evaluated. This study aimed to assess the predictive value of baseline RI derived from dual-time-point ¹⁸F-FDG PET/CT in LAPC patients receiving neoadjuvant therapy. This retrospective analysis included 42 LAPC patients who underwent pretreatment dual-time-point ¹⁸F-FDG PET/CT followed by neoadjuvant FOLFIRINOX. The RI was significantly higher in patients who experienced clinical progression ( n = 24, 57.1%) compared to non-progressors (median: 57.28% vs. 0.57%; P < 0.0001). Among the 37 patients with complete survival follow-up, time-dependent ROC analysis identified an optimal RI cutoff of 23.5% for predicting 2-year mortality. Patients with a high RI (≥ 23.5%) had a significantly shorter median OS (21.5 months vs. not reached; log-rank P = 0.00059). In a multivariable Cox regression model adjusting for CA19-9, histologic grade, tumor location, treatment duration, and SUV parameters, a low RI (< 23.5%) remained independently associated with a reduced risk of death (HR = 0.036; 95% CI: 0.002–0.83; P = 0.038). Pretreatment RI derived from dual-time-point ¹⁸F-FDG PET/CT is a robust and independent predictor of both treatment resistance and overall survival in LAPC patients undergoing neoadjuvant FOLFIRINOX therapy. Its strong discriminatory performance supports its potential for early risk stratification and personalized treatment selection. Prospective validation in larger cohorts is warranted.

Authors

Institutions

Publication Details

Journal
EJNMMI Research
Published
2026-11-19
DOI
https://doi.org/10.1186/s13550-026-01510-z
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pretreatment dual-time-point ¹⁸F-FDG PET/CT for predicting response and survival in locally advanced pancreatic cancer receiving neoadjuvant therapy

Changjing Zuo, Kai Liu, Chao Cheng, Zeyu Zhang et al.
EJNMMI Research
Pancreatic and Hepatic Oncology Research
article

Pretreatment dual-time-point ¹⁸F-FDG PET/CT for predicting response and survival in locally advanced pancreatic cancer receiving neoadjuvant therapy

Changjing Zuo, Kai Liu, Chao Cheng, Zeyu Zhang, Chang Liu
article en

Abstract

Accurately identifying patients with locally advanced pancreatic cancer (LAPC) who are unlikely to respond to neoadjuvant FOLFIRINOX therapy remains a critical unmet need. Conventional anatomic imaging often fails to capture early changes in tumor biology. In contrast, dual-time-point ¹⁸F-FDG PET/CT provides a functional assessment of tumor glycolytic dynamics through the retention index (RI). However, the utility of pretreatment RI for predicting treatment response and overall survival (OS) in LAPC has not been systematically evaluated. This study aimed to assess the predictive value of baseline RI derived from dual-time-point ¹⁸F-FDG PET/CT in LAPC patients receiving neoadjuvant therapy. This retrospective analysis included 42 LAPC patients who underwent pretreatment dual-time-point ¹⁸F-FDG PET/CT followed by neoadjuvant FOLFIRINOX. The RI was significantly higher in patients who experienced clinical progression ( n = 24, 57.1%) compared to non-progressors (median: 57.28% vs. 0.57%; P < 0.0001). Among the 37 patients with complete survival follow-up, time-dependent ROC analysis identified an optimal RI cutoff of 23.5% for predicting 2-year mortality. Patients with a high RI (≥ 23.5%) had a significantly shorter median OS (21.5 months vs. not reached; log-rank P = 0.00059). In a multivariable Cox regression model adjusting for CA19-9, histologic grade, tumor location, treatment duration, and SUV parameters, a low RI (< 23.5%) remained independently associated with a reduced risk of death (HR = 0.036; 95% CI: 0.002–0.83; P = 0.038). Pretreatment RI derived from dual-time-point ¹⁸F-FDG PET/CT is a robust and independent predictor of both treatment resistance and overall survival in LAPC patients undergoing neoadjuvant FOLFIRINOX therapy. Its strong discriminatory performance supports its potential for early risk stratification and personalized treatment selection. Prospective validation in larger cohorts is warranted.

EJNMMI Research
Second Military Medical University (CN), Changhai Hospital (CN)
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon